Information PortalData PortalKnowledge Portal

Data Matrix

Tools & Workflows

Documentation

Ephrin type-B receptor 6 (Protein)

Uniprotkb:O15197

Id:049517b5-4455-5342-bd09-b927658ac343

Analyze

CFDE DD-Knowledge Graph

The CFDE Data Distillery Knowledge Graph contains entities and relationships across the CFDE. View Ephrin type-B receptor 6 's neighborhood in the knowledge graph.

Results found

Linked to

	Label	Description
	TG-100572 bioactivity Ephrin type-B receptor 6 Knowledge Graph Assertion (Entity type)	A Knowledge Graph Assertion from IDG
	Ki-20227 bioactivity Ephrin type-B receptor 6 Knowledge Graph Assertion (Entity type)	A Knowledge Graph Assertion from IDG
	Crizotinib bioactivity Ephrin type-B receptor 6 Knowledge Graph Assertion (Entity type)	A Knowledge Graph Assertion from IDG
	VX-680/MK-0457 bioactivity Ephrin type-B receptor 6 Knowledge Graph Assertion (Entity type)	A Knowledge Graph Assertion from IDG
	CH-5183284 bioactivity Ephrin type-B receptor 6 Knowledge Graph Assertion (Entity type)	A Knowledge Graph Assertion from IDG
	XL-228 bioactivity Ephrin type-B receptor 6 Knowledge Graph Assertion (Entity type)	A Knowledge Graph Assertion from IDG
	compound 20 [PMID: 23489211] bioactivity Ephrin type-B receptor 6 Knowledge Graph Assertion (Entity type)	A Knowledge Graph Assertion from IDG
	EXEL-2880/GSK-1363089 bioactivity Ephrin type-B receptor 6 Knowledge Graph Assertion (Entity type)	A Knowledge Graph Assertion from IDG
	N-(2-chloro-6-methylphenyl)-2-(6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide bioactivity Ephrin type-B receptor 6 Knowledge Graph Assertion (Entity type)	A Knowledge Graph Assertion from IDG
	PD-173955 bioactivity Ephrin type-B receptor 6 Knowledge Graph Assertion (Entity type)	A Knowledge Graph Assertion from IDG

Knowledge Graph Assertion

TG-100572 bioactivity Ephrin type-B receptor 6

Knowledge Graph Assertion (Entity type)

A Knowledge Graph Assertion from IDG

Knowledge Graph Assertion

Ki-20227 bioactivity Ephrin type-B receptor 6

Knowledge Graph Assertion (Entity type)

A Knowledge Graph Assertion from IDG

Knowledge Graph Assertion

Crizotinib bioactivity Ephrin type-B receptor 6

Knowledge Graph Assertion (Entity type)

A Knowledge Graph Assertion from IDG

Knowledge Graph Assertion

VX-680/MK-0457 bioactivity Ephrin type-B receptor 6

Knowledge Graph Assertion (Entity type)

A Knowledge Graph Assertion from IDG

Knowledge Graph Assertion

CH-5183284 bioactivity Ephrin type-B receptor 6

Knowledge Graph Assertion (Entity type)

A Knowledge Graph Assertion from IDG

Knowledge Graph Assertion

XL-228 bioactivity Ephrin type-B receptor 6

Knowledge Graph Assertion (Entity type)

A Knowledge Graph Assertion from IDG

Knowledge Graph Assertion

compound 20 [PMID: 23489211] bioactivity Ephrin type-B receptor 6

Knowledge Graph Assertion (Entity type)

A Knowledge Graph Assertion from IDG

Knowledge Graph Assertion

EXEL-2880/GSK-1363089 bioactivity Ephrin type-B receptor 6

Knowledge Graph Assertion (Entity type)

A Knowledge Graph Assertion from IDG

Knowledge Graph Assertion

N-(2-chloro-6-methylphenyl)-2-(6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide bioactivity Ephrin type-B receptor 6

Knowledge Graph Assertion (Entity type)

A Knowledge Graph Assertion from IDG

Knowledge Graph Assertion

PD-173955 bioactivity Ephrin type-B receptor 6

Knowledge Graph Assertion (Entity type)

A Knowledge Graph Assertion from IDG

DISPLAY PER PAGE

Consortium

Community

Resources

@CFDE Workbench 2025

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

Consortium

Community

Resources

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

@CFDE Workbench 2025

This repository is under review for potential modification in compliance with Administration directives.